These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 24325346)

  • 1. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.
    Bhatia A; Kumar Y
    Expert Rev Clin Immunol; 2014 Jan; 10(1):41-62. PubMed ID: 24325346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
    Poggi A; Musso A; Dapino I; Zocchi MR
    Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
    Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
    J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.
    Whiteside TL; Mandapathil M; Szczepanski M; Szajnik M
    Bull Cancer; 2011 Feb; 98(2):E25-31. PubMed ID: 21339097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricks tumors use to escape from immune control.
    Whiteside TL
    Oral Oncol; 2009 Oct; 45(10):e119-23. PubMed ID: 19467917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Solito S; Marigo I; Pinton L; Damuzzo V; Mandruzzato S; Bronte V
    Ann N Y Acad Sci; 2014 Jun; 1319():47-65. PubMed ID: 24965257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art.
    Fanini F; Fabbri M
    Semin Cell Dev Biol; 2017 Jul; 67():23-28. PubMed ID: 27956165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape.
    Eichmüller SB; Osen W; Mandelboim O; Seliger B
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
    Stewart TJ; Smyth MJ
    Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
    Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
    Messmer MN; Netherby CS; Banik D; Abrams SI
    Cancer Immunol Immunother; 2015 Jan; 64(1):1-13. PubMed ID: 25432147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.
    Daveri E; Vergani E; Shahaj E; Bergamaschi L; La Magra S; Dosi M; Castelli C; Rodolfo M; Rivoltini L; Vallacchi V; Huber V
    Front Immunol; 2020; 11():1214. PubMed ID: 32793185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-derived suppressor cells in human cancer.
    Nagaraj S; Gabrilovich DI
    Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cancer immunotherapy. Importance of overcoming immune suppression].
    Malvicini M; Puchulo G; Matar P; Mazzolini G
    Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camouflage and sabotage: tumor escape from the immune system.
    Poschke I; Mougiakakos D; Kiessling R
    Cancer Immunol Immunother; 2011 Aug; 60(8):1161-71. PubMed ID: 21626032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
    Solito S; Bronte V; Mandruzzato S
    J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.
    Zhang B; Jia H; Liu J; Yang Z; Jiang T; Tang K; Li D; Huang C; Ma J; Shen GX; Ye D; Huang B
    J Immunol; 2010 Dec; 185(12):7199-206. PubMed ID: 21068404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.